CDKN2A and neoplasm: Further ACT experiments revealed that increased p16 expression in T cells significantly impaired their ability to mount an effective anti-tumor immune response by diminishing T cell persistence and promoting terminal exhaustion of tumor-infiltrating T cells in vivo.